Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic melanoma, meeting any of the following criteria:~  * Progressive disease after chemotherapy, radiotherapy, surgery, or immunotherapy~ * No longer responding to standard therapy OR have refused standard therapy~* Unresectable disease~* Measurable or evaluable disease~* No clinical ascites~* No symptomatic pleural effusion~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 12 weeks~* Karnofsky performance status 70-100%~* Bilirubin ≤ 3.0 mg/dL~* Albumin ≥ 3.0 g/dL~* Alkaline phosphatase \< 5 times upper limit of normal (ULN)~* Serum glucose \> 60 mg/dL~* Amylase \< 1.5 times ULN~* Absolute neutrophil count \> 1,500/mm³~* Platelet count \> 100,000/mm³~* No New York Heart Association class III-IV heart failure~* No serious infection requiring treatment with antibiotics~* No known allergy to E. coli drug products (e.g., sargramostim \[GM-CSF\])~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 forms of effective contraception~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 4 weeks since prior anticancer therapy~* At least 4 weeks since prior surgery and recovered~* No concurrent participation in another investigational drug study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- ADI-PEG 20 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).